Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effects of pindolol on renal function

E Wainer, G Boner, J B Rosenfeld

    Clinical Pharmacology and Therapeutics
    |November 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

    Diabetologia·2005
    Same author

    Management of diabetic nephropathy: epidemiology, pathogenesis of nephropathy and factors influencing progression.

    EDTNA/ERCA journal (English ed.)·2005
    Same author

    Dual blockade of the renin-angiotensin system in diabetic nephropathy.

    Diabetic medicine : a journal of the British Diabetic Association·2004
    Same author

    Preliminary results of non-cross-matched "old for old" kidney transplantation.

    Transplantation proceedings·2003
    Same author

    Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2002
    Same author

    Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat.

    Journal of the renin-angiotensin-aldosterone system : JRAAS·2002
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Beta blockers like pindolol can reduce glomerular filtration rate (GFR). While intravenous pindolol lowered GFR, prolonged oral administration did not affect kidney function in hypertensive patients.

    Area of Science:

    • Nephrology
    • Cardiology
    • Pharmacology

    Background:

    • Beta-blockers are known to potentially reduce glomerular filtration rate (GFR).
    • Pindolol is a beta-blocker used in managing hypertension.

    Purpose of the Study:

    • To investigate the renal effects of both intravenous and prolonged oral administration of pindolol.
    • To determine if pindolol impacts GFR in patients with essential hypertension.

    Main Methods:

    • 10 patients with essential hypertension were studied.
    • Inulin clearance, pulse rate, blood pressure, filtration fraction, and plasma renin activity (PRA) were measured.
    • Pindolol was administered intravenously and orally (10-20 mg/day for 6 months).

    Main Results:

    Related Experiment Videos

    • Intravenous pindolol decreased inulin clearance (GFR) and pulse rate, but not blood pressure or filtration fraction.
    • Prolonged oral pindolol significantly reduced blood pressure, pulse rate, and PRA, without altering inulin clearance or filtration fraction.
    • After oral therapy, intravenous pindolol caused a more pronounced reduction in inulin clearance compared to the initial assessment.

    Conclusions:

    • Intravenous pindolol administration leads to a decrease in GFR, likely due to hemodynamic changes.
    • Long-term oral pindolol therapy does not impair GFR in hypertensive patients, despite reductions in blood pressure, pulse rate, and PRA.